IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v16y2015i9p995-1004.html
   My bibliography  Save this article

Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials

Author

Listed:
  • Kristin Kahle-Wrobleski
  • Howard Fillit
  • Jonathan Kurlander
  • Catherine Reed
  • Mark Belger

Abstract

The number of comorbidities, alone or when combined with concomitant medications, did not impact baseline costs of care, perhaps because RCTs often enroll less severely ill and more medically stable patients. However, higher costs were consistently associated with greater functional impairment similar to non-RCT databases. Supplemental sources (e.g., claims databases) are likely needed to better estimate the effects of disease and treatment on costs of illness captured in RCTs for AD. Copyright The Author(s) 2015

Suggested Citation

  • Kristin Kahle-Wrobleski & Howard Fillit & Jonathan Kurlander & Catherine Reed & Mark Belger, 2015. "Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer’s disease clinical trials," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 995-1004, December.
    • Handle: RePEc:spr:eujhec:v:16:y:2015:i:9:p:995-1004
    DOI: 10.1007/s10198-014-0648-7
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-014-0648-7
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-014-0648-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Jerrold Hill & Howard Fillit & Simu Thomas & Sobin Chang, 2006. "Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias," PharmacoEconomics, Springer, vol. 24(3), pages 265-280, March.
    2. Denis Getsios & Kristen Migliaccio-Walle & Jaime Caro, 2007. "NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors," PharmacoEconomics, Springer, vol. 25(12), pages 997-1006, December.
    3. Johannesson, Magnus & Borgquis, Lars & Jonsson, Bengt & Rastam, Lennart, 1991. "The costs of treating hypertension -- an analysis of different cut-off points," Health Policy, Elsevier, vol. 18(2), pages 141-150, July.
    4. Linus Jönsson & Anders Wimo, 2009. "The Cost of Dementia in Europe," PharmacoEconomics, Springer, vol. 27(5), pages 391-403, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Li-Jung Elizabeth Ku & Ming-Chyi Pai & Pei-Yu Shih, 2016. "Economic Impact of Dementia by Disease Severity: Exploring the Relationship between Stage of Dementia and Cost of Care in Taiwan," PLOS ONE, Public Library of Science, vol. 11(2), pages 1-12, February.
    2. Eric Stallard & Bruce Kinosian & Arthur S. Zbrozek & Anatoliy I. Yashin & Henry A. Glick & Yaakov Stern, 2010. "Estimation and Validation of a Multiattribute Model of Alzheimer Disease Progression," Medical Decision Making, , vol. 30(6), pages 625-638, November.
    3. Els Meeuwsen & René Melis & Geert van der Aa & Gertie Golüke-Willemse & Benoit de Leest & Frank van Raak & Carla Schölzel-Dorenbos & Desiree Verheijen & Frans Verhey & Marieke Visser & Claire Wolfs & , 2013. "Cost-Effectiveness of One Year Dementia Follow-Up Care by Memory Clinics or General Practitioners: Economic Evaluation of a Randomised Controlled Trial," PLOS ONE, Public Library of Science, vol. 8(11), pages 1-7, November.
    4. Richard Cimler & Petra Maresova & Jitka Kuhnova & Kamil Kuca, 2019. "Predictions of Alzheimer’s disease treatment and care costs in European countries," PLOS ONE, Public Library of Science, vol. 14(1), pages 1-16, January.
    5. María Noel Pi Alperin & Magali Perquin & Gastón A. Giordana, 2023. "Population ageing and the public finance burden of dementia: A simulation analysis," BCL working papers 170, Central Bank of Luxembourg.
    6. Denis Getsios & Steve Blume & K. Ishak & Grant Maclaine, 2010. "Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 28(5), pages 411-427, May.
    7. Dhammika Deepani Siriwardhana & Kate Walters & Greta Rait & Juan Carlos Bazo-Alvarez & Manuj Chrishantha Weerasinghe, 2018. "Cross-cultural adaptation and psychometric evaluation of the Sinhala version of Lawton Instrumental Activities of Daily Living Scale," PLOS ONE, Public Library of Science, vol. 13(6), pages 1-20, June.
    8. Martina Lundqvist & Jenny Alwin & Lars-Åke Levin, 2019. "Certified service dogs – A cost-effectiveness analysis appraisal," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-13, September.
    9. Rapp, Thomas & Grand, Alain & Cantet, Christelle & Andrieu, Sandrine & Coley, Nicola & Portet, Florence & Vellas, Bruno, 2011. "Public financial support receipt and non-medical resource utilization in Alzheimer's disease results from the PLASA study," Social Science & Medicine, Elsevier, vol. 72(8), pages 1310-1316, April.
    10. Dixon, Josie & Ferdinand, Monique & D'Amico, Francesco & Knapp, Martin, 2015. "Exploring the cost-effectiveness of a one-off screen for dementia (for people aged 75 years in England and Wales)," LSE Research Online Documents on Economics 58109, London School of Economics and Political Science, LSE Library.
    11. Jacques Touchon & Jean Lachaine & Catherine Beauchemin & Anna Granghaud & Benoit Rive & Sébastien Bineau, 2014. "The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 791-800, November.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:16:y:2015:i:9:p:995-1004. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.